Clinical Trial Update: Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update assessing Telaglenastat in combination with radiation therapy and temozolomide for IDH-mutant diffuse astrocytoma or anaplastic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma Idh-mutant

Drugs mentioned

• Telaglenastat (telaglenastat)
• Temodar (Temozolomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3 | Phase 1 | Status: ACTIVE_NOT_RECRUITING